ArticleFrontiers in immunology2023

Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Randall C Dere et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.